High-frequency repetitive transcranial magnetic stimulation to the left dorsolateral prefrontal cortex of patients with Parkinson’s disease and treatment-resistant depression: a pilot study

References

• Akhmadeeva, G. N., Magzhanov, R. V., Tayupova, G. N., Baitimerov, A. R., & Khidiyatova, I. M. (2018). Depression and anxiety in parkinson’s disease. Neuroscience and Behavioral Physiology, 48(5), 636–640.
   Google Scholar
• Aluoja, A., Shlik, J., Vasar, V., Luuk, K., & Leinsalu, M. (1999). Development and psychometric properties of the emotional state questionnaire, a self-report questionnaire for depression and anxiety. Nordic Journal of Psychiatry, 53, 443–449.
   Web of Science ®Google Scholar
• Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An inventory for measuring depression. Archives of General Psychiatry, 4, 561–571.
   PubMed Web of Science ®Google Scholar
• Boggio, P. S., Fregni, F., Bermpohl, F., Mansur, C. G., Rosa, M., Rumi, D. O., … Araujo Silva, M. T. (2005). Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson’s disease and concurrent depression. Movement Disorders, 20, 1178–1184.
   PubMed Web of Science ®Google Scholar
• Cardoso, E. F., Fregni, F., Martins Maia, F., Boggio, P. S., Luis Myczkowski, M., Coracini, K., … Amaro, E. (2008). rTMS treatment for depression in Parkinson’s disease increases BOLD responses in the left prefrontal cortex. The International Journal of Neuropsychopharmacology, 11. doi:10.1017/S1461145707007961
   PubMed Web of Science ®Google Scholar
• Chen, P.-H., & Cheng, S.-J. (2008). Depression in Parkinson Disease: Current Understanding and Treatment. International Journal of Gerontology, 2(4), 172–182.
   Web of Science ®Google Scholar
• Cummings, J. L., & Masterman, D. L. (1999). Depression in patients with Parkinson’s disease. International Journal of Geriatric Psychiatry, 14, 711–718.
   PubMed Web of Science ®Google Scholar
• Epstein, C. M., Evatt, M. L., Funk, A., Girard-Siqueira, L., Lupei, N., Athar, S., … Slaughter, L. (2007). An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson’s disease. Clinical Neurophysiology, 118, 2189–2194.
   PubMed Web of Science ®Google Scholar
• Fava, M. (2003). Diagnosis and definition of treatment-resistant depression. Biological Psychiatry, 53, 649–659.
   PubMed Web of Science ®Google Scholar
• Fekadu, A., Wooderson, S. C., Markopoulo, K., Donaldson, C., Papadopoulos, A., & Cleare, A. J. (2009). What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. Journal of Affective Disorders, 116, 4–11.
   PubMed Web of Science ®Google Scholar
• Fregni, F. (2004). Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease. Journal of Neurology, Nerosurgery & Psychiatry, 75, 1171–1174.
   PubMed Web of Science ®Google Scholar
• Fregni, F., Ono, C. R., Santos, C. M., Bermpohl, F., Buchpiguel, C., Barbosa, E. R., … Valente, K. D. (2006). Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD. Neurology, 66, 1629–1637.
   PubMed Web of Science ®Google Scholar
• George, M. S., Wassermann, E. M., Williams, W. A., Callahan, A., Ketter, T. A., Basser, P., … Post, R. (1995). Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport, 6, 1853–1856.
   PubMed Web of Science ®Google Scholar
• Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., … Dubois, B. (2008). Movement disorder society‐sponsored revision of the unified Parkinson’s disease rating scale (MDS‐UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 23, 2129–2170.
   PubMed Web of Science ®Google Scholar
• Hoehn, M. M., & Yahr, M. D. (1967). Parkinsonism: Onset, progression and mortality. Neurology, 17, 427–442.
   PubMed Web of Science ®Google Scholar
• Jenkinson, C., Fitzpatrick, R. A. Y., Peto, V. I. V., Greenhall, R., & Hyman, N. (1997). The Parkinson’s disease questionnaire (PDQ-39): Development and validation of a Parkinson’s disease summary index score. Age and Ageing, 26, 353–357.
   PubMed Web of Science ®Google Scholar
• Kadastik-Eerme, L., Rosenthal, M., Paju, T., Muldmaa, M., & Taba, P. (2015). Health-related quality of life in Parkinson’s disease: A cross-sectional study focusing on non-motor symptoms. Health and Quality of Life Outcomes, 13, 83.
   PubMed Web of Science ®Google Scholar
• Kadastik-Eerme, L., Taba, N., Asser, T., & Taba, P. (2018). The increasing prevalence of Parkinson’s disease in Estonia. Acta Neurologica Scandinavica, 138, 251–258.
   PubMed Web of Science ®Google Scholar
• Leentjens, A. F., Van Den Akker, M., Metsemakers, J. F., Lousberg, R., & Verhey, F. R. (2003). Higher incidence of depression preceding the onset of Parkinson’s disease: A register study. Movement Disorders, 18, 414–418.
   PubMed Web of Science ®Google Scholar
• Lees, A. J., Hardy, J., & Revesz, T. (2009). Parkinson’s disease. The Lancet, 373, 2055–2066.
   PubMed Web of Science ®Google Scholar
• Lefaucheur, J.-P. (2009). Treatment of Parkinson’s disease by cortical stimulation. Expert Review of Neurotherapeutics, 9, 1755–1771.
   PubMed Web of Science ®Google Scholar
• Lefaucheur, J.-P., André-Obadia, N., Antal, A., Ayache, S. S., Baeken, C., Benninger, D. H., … Garcia-Larrea, L. (2014). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clinical Neurophysiology, 125, 2150–2206.
   PubMed Web of Science ®Google Scholar
• Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., … Aarsland, D. (2012). Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement disorder society task force guidelines. Movement Disorders, 27, 349–356.
   PubMed Web of Science ®Google Scholar
• Mally, J., & Stone, T. W. (1999). Improvement in Parkinsonian symptoms after repetitive transcranial magnetic stimulation. Journal of the Neurological Sciences, 162, 179–184.
   PubMed Web of Science ®Google Scholar
• Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., … Chertkow, H. (2005). The montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53, 695–699.
   PubMed Web of Science ®Google Scholar
• Padberg, F., Zwanzger, P., Thoma, H., Kathmann, N., Haag, C. D., Greenberg, B., … Möller, H.-J. (1999). Repetitive transcranial magnetic stimulation (rTMS) in pharmacothera py-refractory major depression: Comparative study of fast, slow and sham rTMS. Psychiatry Research, 88, 163–171.
   PubMed Web of Science ®Google Scholar
• Pal, E., Nagy, F., Aschermann, Z., Balazs, E., & Kovacs, N. (2010). The impact of left pre frontal repetitive transcranial magnetic stimulation on depression in Parkinson’s disease: A randomized, double-blind, placebo-controlled study. Movement Disorders, 25, 2311–2317.
   PubMed Web of Science ®Google Scholar
• Randver, R. (2018). Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex to alleviate depression and cognitive impairment associated with Parkinson’s disease: A review and clinical implications. Journal of the Neurological Sciences, 393, 88–99.
   PubMed Web of Science ®Google Scholar
• Reijnders, J. S. A. M., Ehrt, U., Weber, W. E. J., Aarsland, D., & Leentjens, A. F. G. (2008). A systematic review of prevalence studies of depression in Parkinson’s disease. Movement Disorders, 23, 183–189.
   PubMed Web of Science ®Google Scholar
• Rossi, S., Hallett, M., Rossini, P. M., & Pascual-Leone, A. (2009). Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clinical Neurophysiology, 120, 2008–2039.
   PubMed Web of Science ®Google Scholar
• Rossini, P. M., Burke, D., Chen, R., Cohen, L. G., Daskalakis, Z., Di Iorio, R., … Ziemann, U. (2015). Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: Basic principles and procedures for routine clinical and research application. An updated report from an I.F.C.N. Committee. Clinical Neurophysiology, 126, 1071–1107.
   PubMed Web of Science ®Google Scholar
• Rush, A. J. (2007). Limitations in efficacy of antidepressant monotherapy. The Journal of Clinical Psychiatry, 68, 8–10.
   PubMed Web of Science ®Google Scholar
• Schrag, A. (2006). Quality of life and depression in Parkinson’s disease. Journal of the Neurological Sciences, 248, 151–157.
   PubMed Web of Science ®Google Scholar
• Schrag, A., Sheikh, S., Quinn, N. P., Lees, A. J., Selai, C., Mathias, C., … Low, P. (2010). A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Movement Disorders, 25, 1077–1081.
   PubMed Web of Science ®Google Scholar
• Schuurman, A. G., Van Den Akker, M., Ensinck, K. T. J. L., Metsemakers, J. F. M., Knottnerus, J. A., Leentjens, A. F. G., & Buntinx, F. (2002). Increased risk of Parkinson’s disease after depression A retrospective cohort study. Neurology, 58, 1501–1504.
   PubMed Web of Science ®Google Scholar
• Schwab, R. S., England, A. C., Poskanzer, D. C., & Young, R. R. (1969). Amantadine in the treatment of Parkinson’s disease. Journal of the American Medical Association, 208, 1168–1170.
   PubMed Web of Science ®Google Scholar
• Slaughter, J. R., Slaughter, K. A., Nichols, D., Holmes, S. E., & Martens, M. P. (2001). Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. The Journal of Neuropsychiatry and Clinical Neurosciences, 13, 187–196.
   PubMed Web of Science ®Google Scholar
• Starkstein, S. E., Preziosi, T. J., Bolduc, P. L., & Robinson, R. G. (1990). Depression in Parkinson’s disease. Journal of Nervous and Mental Disease, 178, 27–31.
   PubMedGoogle Scholar
• Tandberg, E., Larsen, J. P., Aarsland, D., & Cummings, J. L. (1996). The occurrence of depression in Parkinson’s disease: A community-based study. Archives of Neurology, 53, 175–179.
   PubMed Web of Science ®Google Scholar
• Tom, T., & Cummings, J. L. (1998). Depression in Parkinson’s disease. Pharmacological characteristics and treatment. Drugs & Aging, 12, 55–74.
   PubMed Web of Science ®Google Scholar
• Tombaugh, T. N. (2004). Trail making test A and B: Normative data stratified by age and education. Archives of Clinical Neuropsychology, 19, 203–214.
   PubMed Web of Science ®Google Scholar
• Troyer, A. K., Moscovitch, M., Winocur, G., Leach, L., & Freedman, M. (1998). Clustering and switching on verbal fluency tests in Alzheimer’s and Parkinson’s disease. Journal of the International Neuropsychological Society, 4, 137–143.
   PubMed Web of Science ®Google Scholar
• van der Hoek, T. C., Bus, B. A., Matui, P., van der Marck, M. A., Esselink, R. A., & Tendolkar, I. (2011). Prevalence of depression in Parkinson’s disease: Effects of disease stage, motor subtype and gender. Journal of the Neurological Sciences, 310, 220–224.
   PubMed Web of Science ®Google Scholar
• Wagle Shukla, A., Shuster, J. J., Chung, J. W., Vaillancourt, D. E., Patten, C., Ostrem, J., & Okun, M. S. (2016). Repetitive transcranial magnetic stimulation (rTMS) therapy in Parkinson’s disease: A meta-analysis. PM&R, 8, 356–366.
   Google Scholar
• Wechsler, D. (1997). Wechsler adult intelligence scale—3rd edition (WAIS-III). San Antonio, TX: Harcourt Assessment.
   Google Scholar
• Weintraub, D., Morales, K. H., Moberg, P. J., Bilker, W. B., Balderston, C., Duda, J. E., … Stern, M. B. (2005). Antidepressant studies in Parkinson’s disease: A review and meta‐ analysis. Movement Disorders, 20, 1161–1169.
   PubMed Web of Science ®Google Scholar